A major expertise of Mabylon consists of delivering a robust, state-of-art high-throughput technology platform for the identification of diagnostically and therapeutically interesting immunoreactivities in select cohorts of human individuals. Mabylon has developed customized quality-control software enabling titer estimates even in the primary screens.

In this context, Mabylon seeks to enter collaborative efforts with academic and commercial entities, with the goal to advance human medicine and provide important solutions to unmet medical needs.

In addition, Mabylon pursues a number of internal projects aimed at discovering effective, safe human-derived biologicals in the areas of neurology, cardiovascular diseases, and severe food allergies.